Disease Landscape and Forecast Insights

Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these…

In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.4…

Immune checkpoint inhibitors have transformed many oncology settings since their entry into the marketplace just over a decade ago. They are continuing to advance into earlier lines of therapy,…

Antibody-drug conjugates have solidified their position as valuable tools against cancer. The agents combine the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. The…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…

CAR T-cell therapies, such as Gilead / Kite Pharma’s Yescarta and Johnson & Johnson Innovative Medicine’s Carvykti, have given hope to patients with relapsed/refractory (R/R) non-Hodgkin’s…

In 2022, sales of branded MAb biologics in oncology exceeded $43 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5…

Biomarker-driven prescribing is paramount in key oncology indications, particularly breast cancer, ovarian cancer, and prostate cancer. Key to all three indications are PARP inhibitors, such as…

Clarivate Epidemiology’s coverage of BRAF comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,…

Clarivate Epidemiology’s coverage of RAS comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets (the United States, France,…

Immune checkpoint inhibitors have greatly altered the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to treatment of advanced disease, the…

Clarivate Epidemiology’s coverage of epidermal growth factor receptor (EGFR)-mutated tumors comprises epidemiological estimates of key patient populations with the biomarker in the major mature…